ArticleGynecologic oncology reports2024

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.

Bobbie J Rimel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.